USPTO Announces a Cancer Immunotherapy Pilot Program

In February The White House announced a national $1 billion initiative to achieve ten years’ worth of cancer research in the next five years to...

New Life Sciences Examples to Help Examiners (and Applicants) Interpret and Apply the Subject Matter Eligibility Analysis under 35 USC § 101 in View of SCOTUS and CAFC Case Law: Nothing Much New

 On May 6, 2016, the USPTO issued several documents (http://www.uspto.gov/patent/laws-and-regulations/examination-policy/2014-interim-guidance-subject-matter-eligibility-0), including new Subject Matter Eligibility Examples for Life Sciences (including one that is directed to...

Are Proactive Portfolio Reviews Needed After 2015 Gilead Double Patenting Decision?

Gilead Sciences, Inc., Hoffmann-La Roche, Inc., F. Hoffmann-La Roche, Ltd., and Genentech, Inc., v.Natco Pharma Ltd.and Natco Pharma, Inc., 753 F.2d 1208 (Fed. Cir. 2014,...

Means plus Function Claims: The Federal Circuit’s Decision in Williamson v. Citrix Online LLC is Like Déjà vu All Over Again

It had all the elements of a pot-boiler thriller: a rogue government official orchestrating a mutiny against the rule of law, individuals in a plucky...

Update: From USPTO Patent Eligibility Guidelines

This is an update from our newsletter of January 2015. On July 30, 2015, the USPTO issued an update regarding the 2014 Interim Guidance on...

USPTO Introduces Expedited Patent Appeal Pilot

The USPTO is providing a temporary basis under which an appellant may have an ex parte appeal to the Patent Trial and Appeal Board (Board)...

International Design Patent Practice and Highlights of the New Hague Agreement

On May 13, 2015 the US will join the Hague Agreement opening a new path for international design patent fillings.  The overall concept of the...
1 9 10 11 12 13 17

Categories

MWZB Newsletter Signup

Subscribe